Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Royalty Pharma plc is one of them.

Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025. The company completed a $2 billion senior notes offering maturing in 2031, 2035, and 2055, enhancing its ability to acquire long-duration royalty assets, fund deals, and strengthen its capital structure.

The firm continues to benefit from growing adoption of royalties, with 87% of biopharma executives considering them for capital needs. Since its 2020 IPO, the corporation has tripled headcount, invested in data analytics, and streamlined operations through manager internalization. Q2 2025 portfolio receipts rose 20% year-over-year, and the company targets $4.7 billion in receipts by 2030, with mid-teens shareholder returns and dividend growth. These trends position Royalty Pharma plc (NASDAQ:RPRX) among the best pharmaceutical stocks for long-term growth.

Innovation drives its growth, particularly in oncology. Royalty Pharma plc (NASDAQ:RPRX) announced a $2 billion funding deal with Revolution Medicines, including up to $1.25 billion in synthetic royalties on daraxonrasib, a late-stage compound targeting RAS-addicted cancers.

Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth

Royalty Pharma plc (NASDAQ:RPRX) will present at Bernstein’s 2nd Annual Healthcare Forum on September 23, 2025. Analysts remain bullish, with TD Cowen reaffirming a buy rating and a $42 price target, reflecting strong performance and promising future growth.

While we acknowledge the risk and potential of RPRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RPRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.